Drug Trial Radar · NCT00508820
An Open Label Study of Romiplostim in Adult Thrombocytopenic Subjects With ITP
Last checked: Nov 20, 2026Latest source record: Nov 14, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
407
Actual
Start
Feb 1, 2005
Primary completion
Jan 1, 2011
Study completion Mar 1, 2011
Sponsor
- Lead sponsor
- AmgenAmgen (AMGN)
- Sponsor type
- Industry
- First posted
- Jul 30, 2007
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This protocol will provide open label romiplostim to adult thrombocytopenic subjects. Romiplostim will be administered by subcutaneous injection once per week. Dose adjustment will be based on platelet counts, and will be allowed throughout the duration of the study. Rescue therapies are allowed at any time during the study. Reductions in concurrent ITP therapies may occur at any time when platelet counts are \> 50,000.
Conditions
- Idiopathic Thrombocytopenic Purpura
- Thrombocytopenia
- Thrombocytopenic Purpura
Interventions
RomiplostimBiological
Romiplostim will be administered subcutaneously QW. Romiplostim will be manufactured and packaged and distributed using Amgen's clinical study investigational product distribution procedures. Romiplostim is presented as a lyophilized, white powder in 5.0 mL glass vials.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Adverse EventsTime frame: Duration of Treatment plus 30 days or End of Study (whichever is later). Approximately 205 weeks.
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.